Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 676-684

  Ngaimisi, E ^a,b   Mugusi, S ^c,d   Minzi, O M ^b   Sasi, P ^b   Riedel, K D ^e   Suda, A ^a   Ueda, N ^a   Janabi, M ^c   Mugusi, F ^b   Haefeli, W E ^e   Burhenne, J ^e   Aklillu, E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^c MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; EFAVIRENZ; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; BENZOXAZINE DERIVATIVE; CYP2B6 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN; N DEMETHYLASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNSPECIFIC MONOOXYGENASE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; SEX DIFFERENCE; TANZANIA; TREATMENT DURATION; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; HIV INFECTIONS; HYDROXYLATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; PROSPECTIVE STUDY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; HYDROXYLATION; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PHENOTYPE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SEX FACTORS; TANZANIA; CYTOCHROME P-450 CYP2B6; P-GLYCOPROTEINS;

EID: 77958512342     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.172     Document Type: Article

References (38)

1. Mocroft, A. et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 17, 1741-1751 (2003).
2. Bacheler, L. et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75, 4999-5008 (2001).
3. Ledergerber, B. et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353, 863-868 (1999).
4. Paredes, R. et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch. Intern. Med. 160, 1123-1132 (2000).
5. Smith, C.J. et al. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression. HIV Med. 10, 19-27 (2009).
6. Maggiolo, F. et al. Similar adherence rates favor diferent virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin. Infect. Dis. 40, 158-163 (2005).
7. Langmann, P. et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur. J. Med. Res. 7, 309-314 (2002).
8. Ståhle, L., Moberg, L., Svensson, J.O. & Sönnerborg, A. Efavirenz plasma concentrations in HIV-infected patients: inter-and intraindividual variability and clinical efects. Ther. Drug Monit. 26, 267-270 (2004).
9. Núñez, M., González De Requena, D., Gallego, L., Jiménez-Nácher, I., González-Lahoz, J. & Soriano, V. Higher efavirenz plasma levels correlate with development of insomnia. J. Acquir. Immune Defc. Syndr. 28, 399-400 (2001).
10. Marzolini, C., Telenti, A., Decosterd, L.A., Greub, G., Biollaz, J. & Buclin, T. Efavirenz plasma levels can predict treatment failure and central nervous system side efects in HIV-1-infected patients. AIDS 15, 71-75 (2001). (Pubitemid 32055781)
11. Csajka, C. et al. Population pharmacokinetics and efects of efavirenz in patients with human immunodefciency virus infection. Clin. Pharmacol. Ther. 73, 20-30 (2003).
12. Puthanakit, T. et al. Efcacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin. Infect. Dis. 41, 100-107 (2005).
13. Smith, P.F., DiCenzo, R. & Morse, G.D. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 40, 893-905 (2001).
14. Efavirenz (Sustiva). Res. Initiat. Treat Action 6, 22-23 (2000).
15. DuPont-Pharma Laboratories. Sustiva. Allerg. Immunol. (Paris) 30, 302 (1998).
16. Almond, L.M., Hoggard, P.G., Edirisinghe, D., Khoo, S.H. & Back, D.J. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J. Antimicrob. Chemother. 56, 738-744 (2005). (Pubitemid 41487777)
17. Barrett, J.S., Joshi, A.S., Chai, M., Ludden, T.M., Fiske, W.D. & Pieniaszek, H.J. Jr. Population pharmacokinetic meta-analysis with efavirenz. Int. J. Clin. Pharmacol. Ther. 40, 507-519 (2002).
18. Faucette, S.R. et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defnes distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320, 72-80 (2007).
19. Mouly, S. et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72, 1-9 (2002).
20. Zhu, M., Kaul, S., Nandy, P. , Grasela, D.M. & Pfster, M. A model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob. Agents Chemother. 53, 2346-2353 (2009).
21. Ji, P. , Damle, B., Xie, J., Unger, S.E., Grasela, D.M. & Kaul, S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J. Clin. Pharmacol. 48, 948-956 (2008).
22. Ogburn, E.T., Jones, D.R., Masters, A.R., Xu, C., Guo, Y. & Desta, Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identifcation of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38, 1218-1229 (2010).
23. Ward, B.A., Gorski, J.C., Jones, D.R., Hall, S.D., Flockhart, D.A. & Desta, Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306, 287-300 (2003).
24. Kim, R.B. et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101, 289-294 (1998).
25. Haas, D.W. et al. Pharmacogenetics of efavirenz and central nervous system side efects: an Adult AIDS Clinical Trials Group study. AIDS 18, 2391-2400 (2004).
26. Störmer, E., von Moltke, L.L., Perlof, M.D. & Greenblatt, D.J. Diferential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 19, 1038-1045 (2002).
27. Chandler, B. et al. The efects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J. Acquir. Immune Defc. Syndr. 33, 551-556 (2003).
28. Weiss, J., Herzog, M., König, S., Storch, C.H., Ketabi-Kiyanvash, N. & Haefeli, W.E. Induction of multiple drug transporters by efavirenz. J. Pharmacol. Sci. 109, 242-250 (2009).
29. Tang, C., Lin, J.H. & Lu, A.Y. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab. Dispos. 33, 603-613 (2005).
30. Salem, S.A., Rajjayabun, P. , Shepherd, A.M. & Stevenson, I.H. Reduced induction of drug metabolism in the elderly. Age Ageing 7, 68-73 (1978).
31. Mukonzo, J.K. et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br. J. Clin. Pharmacol. 68, 690-699 (2009).
32. Nyakutira, C. et al. High prevalence of the CYP2B6 516G-T(*6) variant and efect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64, 357-365 (2008).
33. Cabrera, S.E. et al. Infuence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodefciency virus patients. Antimicrob. Agents Chemother. 53, 2791-2798 (2009).
34. Fellay, J. et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30-36 (2002).
35. Haas, D.W. et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfnavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis. 192, 1931-1942 (2005).
36. Winzer, R. et al. No infuence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur. J. Med. Res. 8, 531-534 (2003).
37. Nasi, M. et al. MDR1 C3435T genetic polymorphism does not infuence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 17, 1696-1698 (2003).
38. Gehrig, A.K., Mikus, G., Haefeli, W.E. & Burhenne, J. Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantifcation of 12 antiretrovirals in plasma. Rapid Commun. Mass Spectrom. 21, 2704-2716 (2007).